Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia

被引:7
作者
Lynum, Karimah S. Bell [1 ]
Turkoz, Ibrahim [2 ]
Kim, Edward [1 ]
机构
[1] Janssen Sci Affairs LLC, Titusville, NJ 08560 USA
[2] Janssen Res & Dev LLC, Titusville, NJ USA
关键词
early illness; paliperidone palmitate; recently diagnosed; relapse; schizophrenia; ACTING INJECTABLE ANTIPSYCHOTICS; RECENTLY DIAGNOSED SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; RELAPSE PREVENTION; 1ST EPISODE; RISPERIDONE; ADHERENCE; TOLERABILITY; MEDICATION; INITIATION;
D O I
10.1111/eip.12685
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim This post hoc analysis of a double-blind (DB), randomized, placebo-controlled, relapse-prevention study evaluated the effects of paliperidone palmitate once-every-3-months (PP3M) in a subpopulation of adults with early illness schizophrenia (duration <= 5 years) from a clinical trial. Methods Patients received either PP3M or placebo every 3 months in the DB phase. The primary efficacy variable was time from randomization to first relapse. Symptom severity, patient functioning, and safety were also assessed. Results A total of 119 patients who entered the DB phase met the criteria for early illness schizophrenia (PP3M, n = 62; placebo, n = 57). PP3M significantly delayed time to relapse vs placebo (P = .035; hazard ratio, 3.08; 95% CI, 1.08-8.80). Symptomatic control and patient functioning were maintained in the PP3M group but significantly worsened in the placebo group. There were no unexpected tolerability findings. Conclusions PP3M reduced relapse risk and maintained symptomatic and functional improvements compared with placebo in patients with early illness schizophrenia.
引用
收藏
页码:667 / 672
页数:6
相关论文
共 28 条
  • [1] Alphs L., 2015, EARLY INTERVENTION P, V12, P55
  • [2] Rethinking the role of long-acting atypical antipsychotics in the community setting
    Altamura, Alfredo Carlo
    Aguglia, Eugenio
    Bassi, Mariano
    Bogetto, Filippo
    Cappellari, Lodovico
    De Giorgi, Serafino
    Fagiolini, Andrea
    Ferrannini, Luigi
    Girardi, Paolo
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2012, 27 (06) : 336 - 349
  • [3] Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia A Randomized Clinical Trial
    Berwaerts, Joris
    Liu, Yanning
    Gopal, Srihari
    Nuamah, Isaac
    Xu, Haiyan
    Savitz, Adam
    Coppola, Danielle
    Schotte, Alain
    Remmerie, Bart
    Maruta, Nataliya
    Hough, David W.
    [J]. JAMA PSYCHIATRY, 2015, 72 (08) : 830 - 839
  • [4] Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Sliwa, Jennifer Kern
    Ma, Yi-Wen
    Alphs, Larry
    [J]. THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2011, 1 (04) : 111 - 124
  • [5] Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia
    Canuso, Carla M.
    Bossie, Cynthia A.
    Amatniek, Joan
    Turkoz, Ibrahim
    Pandina, Gahan
    Cornblatt, Barbara
    [J]. EARLY INTERVENTION IN PSYCHIATRY, 2010, 4 (01) : 64 - 78
  • [6] Ceskova Eva, 2005, Neuropsychiatr Dis Treat, V1, P179, DOI 10.2147/nedt.1.2.179.61045
  • [7] The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence
    Correll, Christoph U.
    Citrome, Leslie
    Haddad, Peter M.
    Lauriello, John
    Olfson, Mark
    Calloway, Stephen M.
    Kane, John M.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 : 3 - +
  • [8] Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES)
    Dubois, Vincent
    Peuskens, Joseph
    Geerts, Paul
    Detraux, Johan
    [J]. EARLY INTERVENTION IN PSYCHIATRY, 2014, 8 (01) : 39 - 49
  • [9] The evidence for illness progression after relapse in schizophrenia
    Emsley, Robin
    Chiliza, Bonginkosi
    Asmal, Laila
    [J]. SCHIZOPHRENIA RESEARCH, 2013, 148 (1-3) : 117 - 121
  • [10] Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison
    Fu, Dong-Jing
    Bossie, Cynthia A.
    Sliwa, Jennifer K.
    Ma, Yi-Wen
    Alphs, Larry
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (01) : 45 - 55